基于人群的组织学确诊黑素细胞增生自然语言处理分析
IMPORTANCE: Population-based information on the distribution of histologic diagnoses associated with skin biopsies is unknown.…
要点
- 近1/4皮肤活检诊断为黑素细胞增生,其中83.1%为I类良性病变。
- 该数据提供从良性到恶性的黑素细胞病变人群基准频率。
核心结论
- 约四分之一皮肤活检结果为黑素细胞增生,首次提供从良性、异型增生到恶性的人群基础估计。
关键数值与推荐
- MPATH-Dx I类:痣和其他良性增生(如轻度异型增生),通常无需进一步治疗。
- MPATH-Dx II类:中度异型增生和其他低风险病变,可能需窄切缘(<5-mm)再切除。
- MPATH-Dx III类:如原位黑色素瘤和其他高风险病变,需5-mm至1-cm切缘再切除。
- MPATH-Dx IV/V类:浸润性黑色素瘤,需≥1-cm切缘扩大切除及潜在辅助治疗。
- IV类对应stage T1a,V类对应≥stage T1b(基于健康系统癌症登记数据)。
临床怎么用
- 为皮肤科医生提供黑素细胞病变活检结果的人群分布参考,有助于评估活检利用率和病变谱。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Population-based information on the distribution of histologic diagnoses associated with skin biopsies is unknown. Electronic medical records (EMRs) enable automated extraction of pathology report data to improve our epidemiologic understanding of skin biopsy outcomes, specifically those of melanocytic origin. OBJECTIVE: To determine population-based frequencies and distribution of histologically confirmed melanocytic lesions. DESIGN, SETTING, AND PARTICIPANTS: A natural language processing (NLP)-based analysis of EMR pathology reports of adult patients who underwent skin biopsies at a large integrated health care delivery system in the US Pacific Northwest from January 1, 2007, through December 31, 2012. EXPOSURES: Skin biopsy procedure. MAIN OUTCOMES AND MEASURES: The primary outcome was histopathologic diagnosis, obtained using an NLP-based system to process EMR pathology reports. We determined the percentage of diagnoses classified as melanocytic vs nonmelanocytic lesions. Diagnoses classified as melanocytic were further subclassified using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) reporting schema into the following categories: class I (nevi and other benign proliferations such as mildly dysplastic lesions typically requiring no further treatment), class II (moderately dysplastic and other low-risk lesions that may merit narrow reexcision with <5-mm margins), class III (eg, melanoma in situ and other higher-risk lesions warranting reexcision with 5-mm to 1-cm margins), and class IV/V (invasive melanoma requiring wide reexcision with ≥1-cm margins and potential adjunctive therapy). Health system cancer registry data were used to define the percentage of invasive melanoma cases within MPATH-Dx class IV (stage T1a) vs V (≥stage T1b). RESULTS: A total of 80 368 skin biopsies, performed on 47 529 patients, were examined. Nearly 1 in 4 skin biopsies were of melanocytic lesions (23%; n = 18 715), which were distributed according to MPATH-Dx categories as follows: class I, 83.1% (n = 15 558); class II, 8.3% (n = 1548); class III, 4.5% (n = 842); class IV, 2.2% (n = 405); and class V, 1.9% (n = 362). CONCLUSIONS AND RELEVANCE: Approximately one-quarter of skin biopsies resulted in diagnoses of melanocytic proliferations. These data provide the first population-based estimates across the spectrum of melanocytic lesions ranging from benign through dysplastic to malignant. These results may serve as a foundation for future research seeking to understand the epidemiology of melanocytic proliferations and optimization of skin biopsy utilization.
引用
- Lott JP, Boudreau DM, Barnhill RL, et al. Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing. JAMA Dermatol. 2018. PMID: 29094145. doi:10.1001/jamadermatol.2017.4060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。